Using ultrasound to guide treatment for heart failure patients
A Parallel-group, Single-center, Two-arm Treatment Study to Assess the Safety and Effectiveness of Venous Ultrasound Guided Decongestion in Adult Patients Hospitalized with Acute Decompensated Heart Failure.
This study is testing if using ultrasound to guide treatment can help hospitalized heart failure patients feel better by managing fluid buildup in their bodies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT06714409 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility, safety, and effectiveness of using venous ultrasound (VExUS) to guide organ decongestion in patients hospitalized with acute decompensated heart failure (ADHF). A total of 180 patients will be randomly assigned to either the VExUS intervention group, where treatment decisions are informed by ultrasound results, or a standard of care group, where no such information is provided. The study aims to determine if VExUS can help manage venous congestion, a potential risk factor in ADHF. Participants will be monitored every other day during hospitalization, with follow-up assessments conducted six months post-discharge.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are hospitalized with a clinical diagnosis of acute decompensated heart failure and have elevated Pro-BNP levels.
Not a fit: Patients with medical or psychiatric conditions that prevent participation in the study may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes for patients with acute decompensated heart failure.
How similar studies have performed: While the use of ultrasound in managing heart failure is gaining interest, this specific approach using VExUS is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or above * Admitted the ward of Department of Cardiology OUH Ullevål with a clinical diagnosis of ADHFdefined by European Society of Cardiology * Pro-BNP \> 800 ng/l at first day of admission * Capable of giving signed informed consent Exclusion Criteria: \- Any medical or psychiatric condition which in the opinion of the investigatorprecludes participation
Where this trial is running
Oslo
- Department of Nephrology, Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Study coordinator: Bård Waldum-Grevbo, MD, PhD
- Email: uxwabr@ous-hf.no
- Phone: +4722119220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.